INNOFIX 400 Hard Gelatin Capsules 400 mg

Šalis: Tanzanija

kalba: anglų

Šaltinis: Tanzania Medicinces & Medical Devices Authority

Parsisiųsti Prekės savybės (SPC)
04-08-2022

Veiklioji medžiaga:

Cefixime Trihydrate Equivalent to Cefixime

Prieinama:

INNOVA CAPTAB LIMITED, INDIA

ATC kodas:

Third-generation Cephalosporins

INN (Tarptautinis Pavadinimas):

Cefixime Trihydrate Equivalent to Cefixime

Dozė:

400 mg

Vaisto forma:

Hard Gelatin Capsules

Pagaminta:

INNOVA CAPTAB LIMITED, INDIA

Produkto santrauka:

Physical description: Purple/White colored "O" size telescopic cap and body hard gelatin capsule containing white to off white powder.; Local technical representative: GLOBAL DAR ES SALAAM PHARMACY LTD (5768)

Autorizacija statusas:

Registered/Compliant

Leidimo data:

2022-01-10

Prekės savybės

                                SUMMARY OF PRODUCT CHARACTERISTICS (SPC)
1. NAME OF THE FINISHED PHARMACEUTICAL PRODUCT
Cefixime Capsules 400mg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each hard gelatin capsule contains:
Cefixime USP (As Trihydrate)
Eq. to Cefixime anhydrous 400 mg
3. PHARMACEUTICAL FORM
Solid oral dosage form, Hard Gelatin Capsules
Purple / White coloured “0” size telescopic cap and body hard
gelatin capsule
containing white to off white powder.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Cefixime is indicated in the treatment of the following infections
caused by
susceptible strains of the designated microorganisms:
UPPER RESPIRATORY TRACT:
Pharyngitis and tonsillitis caused by S. pyogenes.
MIDDLE EAR:
Otitis
media
caused
by
S.
pneumoniae,
H.
influenzae
(beta-lactamase
positive and negative strains), M. catarrhalis(former B. catarrhalis)
(beta-
lactamase positive and negative strains) and S. pyogenes.
PARANASAL SINUSES:
Sinusitis caused by S. pneumoniae, H. Influenza (beta-lactamase
positive
and
negative
strains),
and
M.
Catarrhalis
(former
B.
catarrhalis)
(beta-
lactamase positive and negative strains).
LOWER RESPIRATORY TRACT:
Acute
bronchitis
caused
by
S.
pneumoniae,
M.
Catarrhalis
(former
B.
catarrhalis) (beta lactamase positive and negative strains) and H.
influenzae (beta-
lactamase positive and negative strains).
URINARY TRACT:
Acute uncomplicated cystitis and urethritis caused by E. coli, P.
mirabilis, and
Klebsiella species.
UNCOMPLICATED GONORRHEA:
Uncomplicated gonorrhea (cervical/urethral and rectal) caused by
Neisseria
gonorrhoeae,
including
penicillinase
(beta-lactamase-positive)
and
non
penicillinase (beta- lactamasenegative) producing strains.
Appropriate cultures should be taken for susceptibility testing before
initiating
treatment with
Cefixime.
If
warranted,
therapy
may
be
instituted
before
susceptibility results are known; however, once these are obtained,
therapy
may need to be adjusted. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION
ADULTS: the recommended dose of INNOFIX is 400 mg daily. This
                                
                                Perskaitykite visą dokumentą
                                
                            

Ieškokite perspėjimų, susijusių su šiuo produktu